CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 121 enrolled
Drug / intervention
caspofungin acetate +1 moredrug
Likely dose
caspofungin acetate 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00717860
NCT00717860Phase 3Completed
CompareCT.gov

A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections

Merck Sharp & Dohme LLC·interventional·Posted Jul 18, 2008·Updated Mar 23, 2017

In Brief

A Phase 3 clinical trial evaluating caspofungin acetate and Comparator: Micafungin sodium for Fungal Infection. Completed, enrolled 121 participants.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFungal Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 18, 2008
Enrollment StartAug 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.0 years ago

Interventions

caspofungin acetatedrug

Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.

Comparator: Micafungin sodiumdrug

Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.